H.C. Wainwright analyst Raghuram Selvaraju believes a death due to capillary leak syndrome is unlikely to lead to a clinical hold on SL-401, Stemline Therapeutics' lead candidate in blastic plasmacytoid dendritic cell neoplasm, a rare blood cancer. The FDA is unlikely to place a clinical hold on the ongoing trial, since capillary leak syndrome is a known safety risk with SL-401 and given the fact that the only agent in this class to receive regulatory approval, Ontak, is also associated with this side-effect, Selvaraju tells investors in a research note. He reiterates a Buy rating on Stemline with a $34 price target. The stock closed Friday up 40c to $6.85.